3 Stocks You Must Follow This Morning: Cell Therapeutics Inc., Aratana Therapeutics Inc., and TherapeuticsMD Inc.

Cell Therapeutics, Aratana Therapeutics, and TherapeuticsMD could be three health care stocks worth watching today. Here’s why.

Jan 6, 2014 at 9:13AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! Let's take a look at three health care stocks you should be following this morning: Cell Therapeutics (NASDAQ:CTIC), Aratana Therapeutics (NASDAQ:PETX), and TherapeuticsMD (NYSEMKT:TXMD).

Cell Therapeutics gets a NICE vote of confidence
Let's first take a look at Cell Therapeutics, which announced yesterday that the National Institute for Health and Care Excellence, or NICE, in the U.K. had issued a Final Appraisal Determination, or FAD, for its blood disorder drug Pixuvri.

NICE's draft guidance determined that Pixuvri was a cost-effective treatment for adults with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL. There were an estimated 1,600 to 1,800 cases of the rare blood disorder in the U.K. last year.

In May 2012, Pixuvri was granted a conditional marketing approval in the E.U. as a monotherapy for the same indication. However, it has not been determined if Pixuvri is effective as a fifth line or greater chemotherapy for refractory patients. Pixuvri is not approved in the United States, but it is being tested as a combination treatment with Roche's Rituxan/MabThera, a common treatment for diseases with B-cell disorders like NHL.

Sales of Pixuvri, the company's only source of revenue, only came in at $0.4 million last quarter. However, analysts believe that annual peak sales could eventually hit $240 million if it is approved in other markets, and the NICE FAD suggests Cell is headed in the right direction.

This positive step for Pixuvri is a second recent catalyst for the company, which announced last week that the FDA had removed the partial clinical hold on its experimental cancer drug tosedostat, which was in phase 1/2 trials. The hold was initiated in June after a patient in the trial died.

Although these two developments are highly positive, investors should be advised that Cell Therapeutics already rallied more than 70% over the past 12 months and trades with a whopping P/S ratio of 220.

Aratana acquires Okapi Sciences
Meanwhile, Aratana Therapeutics, a company focused on pet medications, today announced its acquisition of Okapi Sciences, which has a proprietary pet antiviral platform and five clinical and development stage candidates in its pipeline. Two of Okapi's most promising antiviral products include its feline herpes and feline immunodeficiency virus franchises.

The acquisition was made for approximately $14 million in cash, a promissory note for $15 million with a maturity date of Dec. 31, 2014, and a possible additional payment of $16 million in cash or shares of common stock.

Aratana, which I identified in a previous article as one of the top-performing biotech IPOs of 2013, has no marketed products. However, it announced that it had met all of its 2013 milestone developments in late December -- a clinical study for its osteoarthritis drug for dogs showed promising results, it initiated a study with 150 dogs for its appetite-stimulating drug, and outlined plans for a field study for its drug for postoperative pain in dogs.

Aratana also acquired Vet Therapeutics in October to add veterinary biologics to its pipeline. The combined acquisitions of Vet and Okapi could significantly accelerate the speed at which Aratana's products reach the market, so investors should stay tuned to the company's progress.

TherapeuticsMD provides an update regarding REPLENISH
Last but not least, TherapeuticsMD, a women's health care company, provided an update regarding its phase 3 trial for TX 12-001HR, an experimental treatment for menopause symptoms.

TherapeuticsMD has now completed its 50th site enrollment for the double-blind, placebo-controlled trial, known as REPLENISH. REPLENISH will measure the reduction in the frequency and severity of hot flashes over a 90-day period while checking endometrial protection for a year.

TX 12-001HR is one of the company's four main hormone therapies. According to a study commissioned by the company, the current market for hormone therapies is estimated to be worth over $3.7 billion per year.

TX 12-001HR stands out from other hormone therapies because it is the first and only bioidentical low-dose HRT (hormone replacement therapy) combo. This means it contains two equal low doses of the hormones 17ß-estradiol and progesterone, which is considered a superior option to the current market of "compounded" (customized) menopausal drugs.

If approved by 2016, analysts believe TX 12-001 could generate peak sales of $300 million -- hardly a blockbuster, but not a bad boost for a company that only reported $3.8 million in revenue in fiscal 2012.

Another top stock to watch
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers